Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 20 entries
Sorted by: Best Match Show Resources per page
Universal PCR and antibody testing demonstrate little to no transmission of SARS-CoV-2 in a rural community.

medRxiv : the preprint server for health sciences

Appa A, Takahashi S, Rodriguez-Barraquer I, Chamie G, Sawyer A, Consortium C, Duarte E, Hakim J, Turcios K, Vinden J, Janson O, Manglik A, Peluso MJ, Deeks SG, Henrich TJ, Torres L, Rodgers M, Hackett J, Chiu C, Havlir D, Greenhouse B.
PMID: 32839781
medRxiv. 2020 Aug 17; doi: 10.1101/2020.08.15.20175786.

BACKGROUND: The absence of systematic surveillance for SARS-CoV-2 has curtailed accurate appraisal of transmission intensity. Our objective was to perform case detection of an entire rural community to quantify SARS-CoV-2 transmission using PCR and antibody testing.METHODS: We conducted a...

Cite
Appa A, Takahashi S, Rodriguez-Barraquer I, et al. Universal PCR and antibody testing demonstrate little to no transmission of SARS-CoV-2 in a rural community. medRxiv. 2020;doi: 10.1101/2020.08.15.20175786.
Appa, A., Takahashi, S., Rodriguez-Barraquer, I., Chamie, G., Sawyer, A., Consortium, C., Duarte, E., Hakim, J., Turcios, K., Vinden, J., Janson, O., Manglik, A., Peluso, M. J., Deeks, S. G., Henrich, T. J., Torres, L., Rodgers, M., Hackett, J., Chiu, C., Havlir, D., & Greenhouse, B. (2020). Universal PCR and antibody testing demonstrate little to no transmission of SARS-CoV-2 in a rural community. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2020.08.15.20175786
Appa, Ayesha, et al. "Universal PCR and antibody testing demonstrate little to no transmission of SARS-CoV-2 in a rural community." medRxiv : the preprint server for health sciences vol. (2020). doi: https://doi.org/10.1101/2020.08.15.20175786
Appa A, Takahashi S, Rodriguez-Barraquer I, Chamie G, Sawyer A, Consortium C, Duarte E, Hakim J, Turcios K, Vinden J, Janson O, Manglik A, Peluso MJ, Deeks SG, Henrich TJ, Torres L, Rodgers M, Hackett J, Chiu C, Havlir D, Greenhouse B. Universal PCR and antibody testing demonstrate little to no transmission of SARS-CoV-2 in a rural community. medRxiv. 2020 Aug 17; doi: 10.1101/2020.08.15.20175786. PMID: 32839781; PMCID: PMC7444294.
Copy Download .nbib Format: NLM
Impact of COVID-19 on routine malaria indicators in Uganda: An interrupted time series analysis.

Research square

Namuganga JF, Briggs J, Roh ME, Okiring J, Kisambira Y, Sserwanga A, Kapisi JA, Arinaitwe E, Ebong C, Ssewanyana I, Greenhouse B, Maiteki-Ssebuguzi C, Kamya MR, Staedke SG, Dorsey G, Nankabirwa JI.
PMID: 34426808
Res Sq. 2021 Aug 18; doi: 10.21203/rs.3.rs-819495/v1.

Background In March 2020, the government of Uganda implemented a strict lockdown policy in response to the COVID-19 pandemic. We performed an interrupted time series analysis (ITSA) to assess whether major changes in healthcare seeking behavior, malaria burden, and...

Cite
Namuganga JF, Briggs J, Roh ME, et al. Impact of COVID-19 on routine malaria indicators in Uganda: An interrupted time series analysis. Res Sq. 2021;doi: 10.21203/rs.3.rs-819495/v1.
Namuganga, J. F., Briggs, J., Roh, M. E., Okiring, J., Kisambira, Y., Sserwanga, A., Kapisi, J. A., Arinaitwe, E., Ebong, C., Ssewanyana, I., Greenhouse, B., Maiteki-Ssebuguzi, C., Kamya, M. R., Staedke, S. G., Dorsey, G., & Nankabirwa, J. I. (2021). Impact of COVID-19 on routine malaria indicators in Uganda: An interrupted time series analysis. Research square, . https://doi.org/10.21203/rs.3.rs-819495/v1
Namuganga, Jane Frances, et al. "Impact of COVID-19 on routine malaria indicators in Uganda: An interrupted time series analysis." Research square vol. (2021). doi: https://doi.org/10.21203/rs.3.rs-819495/v1
Namuganga JF, Briggs J, Roh ME, Okiring J, Kisambira Y, Sserwanga A, Kapisi JA, Arinaitwe E, Ebong C, Ssewanyana I, Greenhouse B, Maiteki-Ssebuguzi C, Kamya MR, Staedke SG, Dorsey G, Nankabirwa JI. Impact of COVID-19 on routine malaria indicators in Uganda: An interrupted time series analysis. Res Sq. 2021 Aug 18; doi: 10.21203/rs.3.rs-819495/v1. PMID: 34426808; PMCID: PMC8382131.
Copy Download .nbib Format: NLM
multiSero: open multiplex-ELISA platform for analyzing antibody responses to SARS-CoV-2 infection.

medRxiv : the preprint server for health sciences

Byrum JR, Waltari E, Janson O, Guo SM, Folkesson J, Chhun BB, Vinden J, Ivanov IE, Forst ML, Li H, Larson AG, Wu W, Tato CM, McCutcheon KM, Peluso MJ, Henrich TJ, Deeks SG, Prakash M, Greenhouse B, Pak JE, Mehta SB.
PMID: 34013298
medRxiv. 2021 May 11; doi: 10.1101/2021.05.07.21249238.

Serology has provided valuable diagnostic and epidemiological data on antibody responses to SARS-CoV-2 in diverse patient cohorts. Deployment of high content, multiplex serology platforms across the world, including in low and medium income countries, can accelerate longitudinal epidemiological surveys....

Cite
Byrum JR, Waltari E, Janson O, et al. multiSero: open multiplex-ELISA platform for analyzing antibody responses to SARS-CoV-2 infection. medRxiv. 2021;doi: 10.1101/2021.05.07.21249238.
Byrum, J. R., Waltari, E., Janson, O., Guo, S. M., Folkesson, J., Chhun, B. B., Vinden, J., Ivanov, I. E., Forst, M. L., Li, H., Larson, A. G., Wu, W., Tato, C. M., McCutcheon, K. M., Peluso, M. J., Henrich, T. J., Deeks, S. G., Prakash, M., Greenhouse, B., Pak, J. E., & Mehta, S. B. (2021). multiSero: open multiplex-ELISA platform for analyzing antibody responses to SARS-CoV-2 infection. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.05.07.21249238
Byrum, Janie R, et al. "multiSero: open multiplex-ELISA platform for analyzing antibody responses to SARS-CoV-2 infection." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.05.07.21249238
Byrum JR, Waltari E, Janson O, Guo SM, Folkesson J, Chhun BB, Vinden J, Ivanov IE, Forst ML, Li H, Larson AG, Wu W, Tato CM, McCutcheon KM, Peluso MJ, Henrich TJ, Deeks SG, Prakash M, Greenhouse B, Pak JE, Mehta SB. multiSero: open multiplex-ELISA platform for analyzing antibody responses to SARS-CoV-2 infection. medRxiv. 2021 May 11; doi: 10.1101/2021.05.07.21249238. PMID: 34013298; PMCID: PMC8132273.
Copy Download .nbib Format: NLM
SARS-CoV-2 serology across scales: a framework for unbiased seroprevalence estimation incorporating antibody kinetics and epidemic recency.

medRxiv : the preprint server for health sciences

Takahashi S, Peluso MJ, Hakim J, Turcios K, Janson O, Routledge I, Busch MP, Hoh R, Tai V, Kelly JD, Martin JN, Deeks SG, Henrich TJ, Greenhouse B, Rodríguez-Barraquer I.
PMID: 34545373
medRxiv. 2021 Sep 14; doi: 10.1101/2021.09.09.21263139.

Serosurveys are a key resource for measuring SARS-CoV-2 cumulative incidence. A growing body of evidence suggests that asymptomatic and mild infections (together making up over 95% of all infections) are associated with lower antibody titers than severe infections. Antibody...

Cite
Takahashi S, Peluso MJ, Hakim J, et al. SARS-CoV-2 serology across scales: a framework for unbiased seroprevalence estimation incorporating antibody kinetics and epidemic recency. medRxiv. 2021;doi: 10.1101/2021.09.09.21263139.
Takahashi, S., Peluso, M. J., Hakim, J., Turcios, K., Janson, O., Routledge, I., Busch, M. P., Hoh, R., Tai, V., Kelly, J. D., Martin, J. N., Deeks, S. G., Henrich, T. J., Greenhouse, B., & Rodríguez-Barraquer, I. (2021). SARS-CoV-2 serology across scales: a framework for unbiased seroprevalence estimation incorporating antibody kinetics and epidemic recency. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.09.09.21263139
Takahashi, Saki, et al. "SARS-CoV-2 serology across scales: a framework for unbiased seroprevalence estimation incorporating antibody kinetics and epidemic recency." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.09.09.21263139
Takahashi S, Peluso MJ, Hakim J, Turcios K, Janson O, Routledge I, Busch MP, Hoh R, Tai V, Kelly JD, Martin JN, Deeks SG, Henrich TJ, Greenhouse B, Rodríguez-Barraquer I. SARS-CoV-2 serology across scales: a framework for unbiased seroprevalence estimation incorporating antibody kinetics and epidemic recency. medRxiv. 2021 Sep 14; doi: 10.1101/2021.09.09.21263139. PMID: 34545373; PMCID: PMC8452112.
Copy Download .nbib Format: NLM
B Cell Receptor Repertoire Analysis in Malaria-Naive and Malaria-Experienced Individuals Reveals Unique Characteristics of Atypical Memory B Cells.

mSphere

Braddom AE, Bol S, Gonzales SJ, Reyes RA, Musinguzi K, Nankya F, Ssewanyana I, Greenhouse B, Bunnik EM.
PMID: 34523978
mSphere. 2021 Oct 27;6(5):e0072621. doi: 10.1128/mSphere.00726-21. Epub 2021 Sep 15.

Malaria, caused by parasites of the

Cite
Braddom AE, Bol S, Gonzales SJ, et al. B Cell Receptor Repertoire Analysis in Malaria-Naive and Malaria-Experienced Individuals Reveals Unique Characteristics of Atypical Memory B Cells. mSphere. 2021;6(5):e0072621doi: 10.1128/mSphere.00726-21.
Braddom, A. E., Bol, S., Gonzales, S. J., Reyes, R. A., Musinguzi, K., Nankya, F., Ssewanyana, I., Greenhouse, B., & Bunnik, E. M. (2021). B Cell Receptor Repertoire Analysis in Malaria-Naive and Malaria-Experienced Individuals Reveals Unique Characteristics of Atypical Memory B Cells. mSphere, 6(5), e0072621. https://doi.org/10.1128/mSphere.00726-21
Braddom, Ashley E, et al. "B Cell Receptor Repertoire Analysis in Malaria-Naive and Malaria-Experienced Individuals Reveals Unique Characteristics of Atypical Memory B Cells." mSphere vol. 6,5 (2021): e0072621. doi: https://doi.org/10.1128/mSphere.00726-21
Braddom AE, Bol S, Gonzales SJ, Reyes RA, Musinguzi K, Nankya F, Ssewanyana I, Greenhouse B, Bunnik EM. B Cell Receptor Repertoire Analysis in Malaria-Naive and Malaria-Experienced Individuals Reveals Unique Characteristics of Atypical Memory B Cells. mSphere. 2021 Oct 27;6(5):e0072621. doi: 10.1128/mSphere.00726-21. Epub 2021 Sep 15. PMID: 34523978; PMCID: PMC8550134.
Copy Download .nbib Format: NLM
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay.

Science advances

Peluso MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, Turcios K, Janson O, Munter SE, Thanh C, Donatelli J, Nixon CC, Hoh R, Tai V, Fehrman EA, Hernandez Y, Spinelli MA, Gandhi M, Palafox MA, Vallari A, Rodgers MA, Prostko J, Hackett J, Trinh L, Wrin T, Petropoulos CJ, Chiu CY, Norris PJ, DiGermanio C, Stone M, Busch MP, Elledge SK, Zhou XX, Wells JA, Shu A, Kurtz TW, Pak JE, Wu W, Burbelo PD, Cohen JI, Rutishauser RL, Martin JN, Deeks SG, Henrich TJ, Rodriguez-Barraquer I, Greenhouse B.
PMID: 34330709
Sci Adv. 2021 Jul 30;7(31). doi: 10.1126/sciadv.abh3409. Print 2021 Jul.

Interpretation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurveillance studies is limited by poorly defined performance of antibody assays over time in individuals with different clinical presentations. We measured antibody responses in plasma samples from 128 individuals over...

Cite
Peluso MJ, Takahashi S, Hakim J, et al. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Sci Adv. 2021;7(31)doi: 10.1126/sciadv.abh3409.
Peluso, M. J., Takahashi, S., Hakim, J., Kelly, J. D., Torres, L., Iyer, N. S., Turcios, K., Janson, O., Munter, S. E., Thanh, C., Donatelli, J., Nixon, C. C., Hoh, R., Tai, V., Fehrman, E. A., Hernandez, Y., Spinelli, M. A., Gandhi, M., Palafox, M. A., Vallari, A., Rodgers, M. A., Prostko, J., Hackett, J., Trinh, L., Wrin, T., Petropoulos, C. J., Chiu, C. Y., Norris, P. J., DiGermanio, C., Stone, M., Busch, M. P., Elledge, S. K., Zhou, X. X., Wells, J. A., Shu, A., Kurtz, T. W., Pak, J. E., Wu, W., Burbelo, P. D., Cohen, J. I., Rutishauser, R. L., Martin, J. N., Deeks, S. G., Henrich, T. J., Rodriguez-Barraquer, I., & Greenhouse, B. (2021). SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Science advances, 7(31), . https://doi.org/10.1126/sciadv.abh3409
Peluso, Michael J, et al. "SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay." Science advances vol. 7,31 (2021). doi: https://doi.org/10.1126/sciadv.abh3409
Peluso MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, Turcios K, Janson O, Munter SE, Thanh C, Donatelli J, Nixon CC, Hoh R, Tai V, Fehrman EA, Hernandez Y, Spinelli MA, Gandhi M, Palafox MA, Vallari A, Rodgers MA, Prostko J, Hackett J, Trinh L, Wrin T, Petropoulos CJ, Chiu CY, Norris PJ, DiGermanio C, Stone M, Busch MP, Elledge SK, Zhou XX, Wells JA, Shu A, Kurtz TW, Pak JE, Wu W, Burbelo PD, Cohen JI, Rutishauser RL, Martin JN, Deeks SG, Henrich TJ, Rodriguez-Barraquer I, Greenhouse B. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Sci Adv. 2021 Jul 30;7(31). doi: 10.1126/sciadv.abh3409. Print 2021 Jul. PMID: 34330709; PMCID: PMC8324059.
Copy Download .nbib Format: NLM
Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2.

medRxiv : the preprint server for health sciences

Routledge I, Takahashi S, Epstein A, Hakim J, Janson O, Turcios K, Vinden J, Risos JT, Baniqued MR, Pham L, Di Germanio C, Busch M, Kushel M, Greenhouse B, Rodríguez-Barraquer I.
PMID: 34642695
medRxiv. 2021 Oct 20; doi: 10.1101/2021.10.06.21264573.

BACKGROUND: As COVID-19 vaccines continue to be rolled-out, the "double burden" of health disparities in both exposure to infection and vaccination coverage intersect to determine the current and future patterns of infection, immunity, and mortality. Serology provides a unique...

Cite
Routledge I, Takahashi S, Epstein A, et al. Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2. medRxiv. 2021;doi: 10.1101/2021.10.06.21264573.
Routledge, I., Takahashi, S., Epstein, A., Hakim, J., Janson, O., Turcios, K., Vinden, J., Risos, J. T., Baniqued, M. R., Pham, L., Di Germanio, C., Busch, M., Kushel, M., Greenhouse, B., & Rodríguez-Barraquer, I. (2021). Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.10.06.21264573
Routledge, Isobel, et al. "Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.10.06.21264573
Routledge I, Takahashi S, Epstein A, Hakim J, Janson O, Turcios K, Vinden J, Risos JT, Baniqued MR, Pham L, Di Germanio C, Busch M, Kushel M, Greenhouse B, Rodríguez-Barraquer I. Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2. medRxiv. 2021 Oct 20; doi: 10.1101/2021.10.06.21264573. PMID: 34642695; PMCID: PMC8509086.
Copy Download .nbib Format: NLM
Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2.

medRxiv : the preprint server for health sciences

Routledge I, Takahashi S, Epstein A, Hakim J, Janson O, Turcios K, Vinden J, Risos JT, Baniqued MR, Pham L, Di Germanio C, Busch M, Kushel M, Greenhouse B, Rodríguez-Barraquer I.
PMID: 34642695
medRxiv. 2021 Oct 20; doi: 10.1101/2021.10.06.21264573.

BACKGROUND: As COVID-19 vaccines continue to be rolled-out, the "double burden" of health disparities in both exposure to infection and vaccination coverage intersect to determine the current and future patterns of infection, immunity, and mortality. Serology provides a unique...

Cite
Routledge I, Takahashi S, Epstein A, et al. Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2. medRxiv. 2021;doi: 10.1101/2021.10.06.21264573.
Routledge, I., Takahashi, S., Epstein, A., Hakim, J., Janson, O., Turcios, K., Vinden, J., Risos, J. T., Baniqued, M. R., Pham, L., Di Germanio, C., Busch, M., Kushel, M., Greenhouse, B., & Rodríguez-Barraquer, I. (2021). Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.10.06.21264573
Routledge, Isobel, et al. "Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.10.06.21264573
Routledge I, Takahashi S, Epstein A, Hakim J, Janson O, Turcios K, Vinden J, Risos JT, Baniqued MR, Pham L, Di Germanio C, Busch M, Kushel M, Greenhouse B, Rodríguez-Barraquer I. Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2. medRxiv. 2021 Oct 20; doi: 10.1101/2021.10.06.21264573. PMID: 34642695; PMCID: PMC8509086.
Copy Download .nbib Format: NLM
Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2.

medRxiv : the preprint server for health sciences

Routledge I, Takahashi S, Epstein A, Hakim J, Janson O, Turcios K, Vinden J, Risos JT, Baniqued MR, Pham L, Di Germanio C, Busch M, Kushel M, Greenhouse B, Rodríguez-Barraquer I.
PMID: 34642695
medRxiv. 2021 Oct 20; doi: 10.1101/2021.10.06.21264573.

BACKGROUND: As COVID-19 vaccines continue to be rolled-out, the "double burden" of health disparities in both exposure to infection and vaccination coverage intersect to determine the current and future patterns of infection, immunity, and mortality. Serology provides a unique...

Cite
Routledge I, Takahashi S, Epstein A, et al. Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2. medRxiv. 2021;doi: 10.1101/2021.10.06.21264573.
Routledge, I., Takahashi, S., Epstein, A., Hakim, J., Janson, O., Turcios, K., Vinden, J., Risos, J. T., Baniqued, M. R., Pham, L., Di Germanio, C., Busch, M., Kushel, M., Greenhouse, B., & Rodríguez-Barraquer, I. (2021). Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.10.06.21264573
Routledge, Isobel, et al. "Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.10.06.21264573
Routledge I, Takahashi S, Epstein A, Hakim J, Janson O, Turcios K, Vinden J, Risos JT, Baniqued MR, Pham L, Di Germanio C, Busch M, Kushel M, Greenhouse B, Rodríguez-Barraquer I. Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2. medRxiv. 2021 Oct 20; doi: 10.1101/2021.10.06.21264573. PMID: 34642695; PMCID: PMC8509086.
Copy Download .nbib Format: NLM
Longitudinal analysis of FcRL5 expression and clonal relationships among classical and atypical memory B cells following malaria.

Malaria journal

Gonzales SJ, Bol S, Braddom AE, Sullivan R, Reyes RA, Ssewanyana I, Eggers E, Greenhouse B, Bunnik EM.
PMID: 34758841
Malar J. 2021 Nov 10;20(1):435. doi: 10.1186/s12936-021-03970-1.

BACKGROUND: Chronic and frequently recurring infectious diseases, such as malaria, are associated with expanded populations of atypical memory B cells (MBCs). These cells are different from classical MBCs by the lack of surface markers CD21 and CD27 and increased...

Cite
Gonzales SJ, Bol S, Braddom AE, et al. Longitudinal analysis of FcRL5 expression and clonal relationships among classical and atypical memory B cells following malaria. Malar J. 2021;20(1):435doi: 10.1186/s12936-021-03970-1.
Gonzales, S. J., Bol, S., Braddom, A. E., Sullivan, R., Reyes, R. A., Ssewanyana, I., Eggers, E., Greenhouse, B., & Bunnik, E. M. (2021). Longitudinal analysis of FcRL5 expression and clonal relationships among classical and atypical memory B cells following malaria. Malaria journal, 20(1), 435. https://doi.org/10.1186/s12936-021-03970-1
Gonzales, S Jake, et al. "Longitudinal analysis of FcRL5 expression and clonal relationships among classical and atypical memory B cells following malaria." Malaria journal vol. 20,1 (2021): 435. doi: https://doi.org/10.1186/s12936-021-03970-1
Gonzales SJ, Bol S, Braddom AE, Sullivan R, Reyes RA, Ssewanyana I, Eggers E, Greenhouse B, Bunnik EM. Longitudinal analysis of FcRL5 expression and clonal relationships among classical and atypical memory B cells following malaria. Malar J. 2021 Nov 10;20(1):435. doi: 10.1186/s12936-021-03970-1. PMID: 34758841; PMCID: PMC8579674.
Copy Download .nbib Format: NLM
SARS-CoV-2 PCR and antibody testing for an entire rural community: methods and feasibility of high-throughput testing procedures.

Archives of public health = Archives belges de sante publique

Appa A, Chamie G, Sawyer A, Baltzell K, Dippell K, Ribeiro S, Duarte E, Vinden J, Consortium C, Kramer-Feldman J, Rahdari S, MacIntosh D, Nicholson K, Im J, Havlir D, Greenhouse B.
PMID: 34233752
Arch Public Health. 2021 Jul 07;79(1):125. doi: 10.1186/s13690-021-00647-8.

BACKGROUND: Early in the pandemic, inadequate SARS-CoV-2 testing limited understanding of transmission. Chief among barriers to large-scale testing was unknown feasibility, particularly in non-urban areas. Our objective was to report methods of high-volume, comprehensive SARS-CoV-2 testing, offering one model...

Cite
Appa A, Chamie G, Sawyer A, et al. SARS-CoV-2 PCR and antibody testing for an entire rural community: methods and feasibility of high-throughput testing procedures. Arch Public Health. 2021;79(1):125doi: 10.1186/s13690-021-00647-8.
Appa, A., Chamie, G., Sawyer, A., Baltzell, K., Dippell, K., Ribeiro, S., Duarte, E., Vinden, J., Consortium, C., Kramer-Feldman, J., Rahdari, S., MacIntosh, D., Nicholson, K., Im, J., Havlir, D., & Greenhouse, B. (2021). SARS-CoV-2 PCR and antibody testing for an entire rural community: methods and feasibility of high-throughput testing procedures. Archives of public health = Archives belges de sante publique, 79(1), 125. https://doi.org/10.1186/s13690-021-00647-8
Appa, Ayesha, et al. "SARS-CoV-2 PCR and antibody testing for an entire rural community: methods and feasibility of high-throughput testing procedures." Archives of public health = Archives belges de sante publique vol. 79,1 (2021): 125. doi: https://doi.org/10.1186/s13690-021-00647-8
Appa A, Chamie G, Sawyer A, Baltzell K, Dippell K, Ribeiro S, Duarte E, Vinden J, Consortium C, Kramer-Feldman J, Rahdari S, MacIntosh D, Nicholson K, Im J, Havlir D, Greenhouse B. SARS-CoV-2 PCR and antibody testing for an entire rural community: methods and feasibility of high-throughput testing procedures. Arch Public Health. 2021 Jul 07;79(1):125. doi: 10.1186/s13690-021-00647-8. PMID: 34233752; PMCID: PMC8261397.
Copy Download .nbib Format: NLM
SARS-CoV-2 PCR and antibody testing for an entire rural community: methods and feasibility of high-throughput testing procedures.

medRxiv : the preprint server for health sciences

Appa A, Chamie G, Sawyer A, Baltzell K, Dippel K, Ribeiro S, Duarte E, Vinden J, Consortium C, Kramer-Feldman J, Rahdari S, MacIntosh D, Nicholson K, Im J, Havlir D, Greenhouse B.
PMID: 32511482
medRxiv. 2020 May 30; doi: 10.1101/2020.05.29.20116426.

High-volume, community-wide ascertainment of SARS-CoV-2 prevalence by PCR and antibody testing was successfully performed using a community-led, drive-through model with strong operational support, well-trained testing units, and an effective technical platform.

Cite
Appa A, Chamie G, Sawyer A, et al. SARS-CoV-2 PCR and antibody testing for an entire rural community: methods and feasibility of high-throughput testing procedures. medRxiv. 2020;doi: 10.1101/2020.05.29.20116426.
Appa, A., Chamie, G., Sawyer, A., Baltzell, K., Dippel, K., Ribeiro, S., Duarte, E., Vinden, J., Consortium, C., Kramer-Feldman, J., Rahdari, S., MacIntosh, D., Nicholson, K., Im, J., Havlir, D., & Greenhouse, B. (2020). SARS-CoV-2 PCR and antibody testing for an entire rural community: methods and feasibility of high-throughput testing procedures. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2020.05.29.20116426
Appa, Ayesha, et al. "SARS-CoV-2 PCR and antibody testing for an entire rural community: methods and feasibility of high-throughput testing procedures." medRxiv : the preprint server for health sciences vol. (2020). doi: https://doi.org/10.1101/2020.05.29.20116426
Appa A, Chamie G, Sawyer A, Baltzell K, Dippel K, Ribeiro S, Duarte E, Vinden J, Consortium C, Kramer-Feldman J, Rahdari S, MacIntosh D, Nicholson K, Im J, Havlir D, Greenhouse B. SARS-CoV-2 PCR and antibody testing for an entire rural community: methods and feasibility of high-throughput testing procedures. medRxiv. 2020 May 30; doi: 10.1101/2020.05.29.20116426. PMID: 32511482; PMCID: PMC7273250.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 20 entries